KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Profit After Tax (2016 - 2025)

Emergent BioSolutions (EBS) has 15 years of Profit After Tax data on record, last reported at -$54.6 million in Q4 2025.

  • For Q4 2025, Profit After Tax fell 74.44% year-over-year to -$54.6 million; the TTM value through Dec 2025 reached $52.6 million, up 127.6%, while the annual FY2025 figure was $52.6 million, 127.6% up from the prior year.
  • Profit After Tax reached -$54.6 million in Q4 2025 per EBS's latest filing, down from $51.2 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $193.1 million in Q4 2021 and bottomed at -$283.1 million in Q2 2024.
  • Average Profit After Tax over 5 years is -$44.3 million, with a median of -$35.8 million recorded in 2021.
  • Peak YoY movement for Profit After Tax: crashed 3947.83% in 2023, then skyrocketed 655.56% in 2025.
  • A 5-year view of Profit After Tax shows it stood at $193.1 million in 2021, then crashed by 134.7% to -$67.0 million in 2022, then rose by 26.12% to -$49.5 million in 2023, then surged by 36.77% to -$31.3 million in 2024, then plummeted by 74.44% to -$54.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Profit After Tax were -$54.6 million in Q4 2025, $51.2 million in Q3 2025, and -$12.0 million in Q2 2025.